Teva Pharmaceutical Industries Ltd. ADR (TEVA): Price and Financial Metrics


Teva Pharmaceutical Industries Ltd. ADR (TEVA): $10.73

-0.03 (-0.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TEVA POWR Grades

  • Value is the dimension where TEVA ranks best; there it ranks ahead of 97.23% of US stocks.
  • The strongest trend for TEVA is in Growth, which has been heading down over the past 177 days.
  • TEVA's current lowest rank is in the Momentum metric (where it is better than 15.61% of US stocks).

TEVA Stock Summary

  • TEVA has a higher market value than 85.26% of US stocks; more precisely, its current market capitalization is $11,917,218,801.
  • TEVA's went public 32.89 years ago, making it older than 85.83% of listed US stocks we're tracking.
  • In terms of twelve month growth in earnings before interest and taxes, TEVA PHARMACEUTICAL INDUSTRIES LTD is reporting a growth rate of -156.13%; that's higher than just 10% of US stocks.
  • If you're looking for stocks that are quantitatively similar to TEVA PHARMACEUTICAL INDUSTRIES LTD, a group of peers worth examining would be BAX, XRAY, XRX, AGFS, and OBLG.
  • TEVA's SEC filings can be seen here. And to visit TEVA PHARMACEUTICAL INDUSTRIES LTD's official web site, go to www.tevapharm.com.

TEVA Valuation Summary

  • In comparison to the median Healthcare stock, TEVA's EV/EBIT ratio is 367.98% lower, now standing at -27.2.
  • Over the past 243 months, TEVA's EV/EBIT ratio has gone down 47.2.

Below are key valuation metrics over time for TEVA.

Stock Date P/S P/B P/E EV/EBIT
TEVA 2023-01-30 0.8 1.3 -8.8 -27.2
TEVA 2023-01-27 0.8 1.3 -8.9 -27.3
TEVA 2023-01-26 0.8 1.3 -8.8 -27.2
TEVA 2023-01-25 0.7 1.3 -8.8 -27.2
TEVA 2023-01-24 0.8 1.3 -8.8 -27.2
TEVA 2023-01-23 0.8 1.3 -8.9 -27.3

TEVA Growth Metrics

    Its 3 year revenue growth rate is now at -13.97%.
  • Its year over year revenue growth rate is now at -4.45%.
  • Its 5 year net cashflow from operations growth rate is now at -73.17%.
TEVA's revenue has moved down $1,090,000,000 over the prior 52 weeks.

The table below shows TEVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 15,142 1,073 -1,290
2022-06-30 15,434 1,059 -1,054
2022-03-31 15,558 1,154 -615
2021-12-31 15,878 798 417
2021-09-30 16,232 673 726
2021-06-30 16,323 451 -3,915

TEVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TEVA has a Quality Grade of C, ranking ahead of 57.93% of graded US stocks.
  • TEVA's asset turnover comes in at 0.33 -- ranking 140th of 682 Pharmaceutical Products stocks.
  • LFVN, ONVO, and ANAB are the stocks whose asset turnover ratios are most correlated with TEVA.

The table below shows TEVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.330 0.468 0.064
2021-06-30 0.329 0.469 -0.088
2021-03-31 0.319 0.463 -0.097
2020-12-31 0.316 0.464 -0.102
2020-09-30 0.298 0.471 -0.108
2020-06-30 0.293 0.462 0.018

TEVA Stock Price Chart Interactive Chart >

Price chart for TEVA

TEVA Price/Volume Stats

Current price $10.73 52-week high $11.44
Prev. close $10.76 52-week low $6.78
Day low $10.65 Volume 5,287,100
Day high $10.78 Avg. volume 10,074,438
50-day MA $9.66 Dividend yield N/A
200-day MA $8.89 Market Cap 11.92B

Teva Pharmaceutical Industries Ltd. ADR (TEVA) Company Bio


Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces, and markets, generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Established in 1901, the company markets 3,500 generic and proprietary products to 60 countries worldwide. Teva competes against other large pharmaceutical companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline. Kare Schulz currently serves as Teva’s President, Chairman of the Board, and Chief Executive Officer, overseeing an international workforce of around 38,000 employees.


TEVA Latest News Stream


Event/Time News Detail
Loading, please wait...

TEVA Latest Social Stream


Loading social stream, please wait...

View Full TEVA Social Stream

Latest TEVA News From Around the Web

Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.

10 Hot Healthcare Stocks To Buy Now

In this article, we discuss the 10 hot healthcare stocks to buy now. If you want to read about some more hot healthcare stocks to buy now, go directly to 5 Hot Healthcare Stocks To Buy Now. The rise of consumer prices has often lagged behind healthcare inflation, which includes costs for doctor visits, surgeries, […]

Yahoo | February 3, 2023

Is Teva Pharmaceutical Industries (TEVA) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Yahoo | January 27, 2023

Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?

Shareholders of Catalyst Pharmaceuticals (NASDAQ: CPRX) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries (NYSE: TEVA), was planning to make a generic version of its only marketed drug, Firdapse. With Catalyst's shares falling 30% in a day before slightly recovering, it's clear that the market is interpreting Teva's actions as severely threatening, and it's reasonable for investors to wonder if it's time to start looking for the door. First, let's take a moment to understand what Firdapse means for Catalyst Pharmaceuticals.

Yahoo | January 26, 2023

Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More

Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.

Yahoo | January 25, 2023

Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025

When the lights went out on 2022, all three major U.S. stock indexes had delivered their worst returns since 2008. While the Nasdaq losing a third of its value in such a short time frame is undoubtedly brutal for short-term traders, it represents a generational opportunity for patient investors to snag high-quality stocks at a discount. The first surefire bargain that has the potential to double your money by mid-decade is brand-name and generic-drug producer Teva Pharmaceutical Industries (NYSE: TEVA).

Yahoo | January 25, 2023

Read More 'TEVA' Stories Here

TEVA Price Returns

1-mo 2.00%
3-mo 18.17%
6-mo -3.25%
1-year 26.83%
3-year -11.76%
5-year -42.44%
YTD 17.65%
2022 13.86%
2021 -16.99%
2020 -1.53%
2019 -36.45%
2018 -18.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6929 seconds.